ArticleScientific reports2025
Survival benefits of primary tumor resection in metastatic differentiated thyroid cancer: an analysis of SEER data.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Recurrence patterns and survival outcomes in advanced papillary thyroid carcinoma: a retrospective cohort analysis.Updates in surgery · 2026Article
- Article
- Adrenal metastases of differentiated thyroid cancer: clinicopathological characteristics and prognostic factors.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metastatic differentiated thyroid cancer (mDTC) can exhibit aggressive growth and disseminate to distant organs, thereby reducing survival rates. The benefits of primary tumor resection (PTR) for patients with mDTC are still debated. In this study, we utilized the Surveillance, Epidemiology, and End Results (SEER) database to evaluate mDTC patients, focusing on the impact of organ-specific metastases and the number of metastatic sites on prognosis, as well as the potential efficacy of PTR as a therapeutic intervention. 904 patients with mDTC at initial diagnosis from 2010 to 2015 were studied. Lung and bone were the most common sites of metastasis. Patients with brain, lung and liver metastasis had significantly worse overall survival (OS) (all p < 0.05) and cancer-specific survival (CSS) (all p < 0.05). Among all the patients, 550 (60.84%) underwent PTR, which was associated with reduced risk of overall mortality (OM) and cancer-specific mortality (CSM) (all p < 0.05). When analyzing different metastatic patterns, PTR significantly lowered the risk of OM and CSM for patients with bone, brain, lung, liver, or distant lymph node (DLN) involvement (all p < 0.05). Surgical resection also improved OS and CSS (both p < 0.05) in patients with multiple organ involvement or one/two metastases. Our findings suggest that PTR may confer benefits to select individuals with metastatic DTC. To validate these results and facilitate their integration into clinical practice, multicenter prospective studies are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.